Concerns & Risks -- 7.3/10
McKesson is the dominant #1 player in a textbook oligopoly with a strong catalyst pipeline
and manageable risk profile. At ~22-27x earnings, the stock trades at a meaningful premium to
historical distribution multiples, reflecting the market recognition of GLP-1 tailwinds,
oncology platform growth, and consistent execution. The primary risks are opioid litigation
tail exposure, drug pricing reform overhang, GLP-1 concentration, and elevated valuation that
demands continued 15%+ EPS growth. The risk/reward is favorable given the secular growth
vectors and under-promise/over-deliver management culture, but the starting valuation leaves
limited margin for error on any growth disappointment.
Weight: 15%
P/E (TTM)
~27x
Premium to 5Y avg ~18-20x
Fwd P/E (FY2026E)
~22.6x
$883.34 / ~$39.00 adj. EPS
FCF Yield
~4.3%
~$4.6B / $108.2B mkt cap
EV/EBITDA
~18x
vs 5Y avg ~14-15x
Valuation Table
| Metric |
Current |
5Y Avg (est.) |
Commentary |
| P/E (TTM) |
~27x |
~18-20x |
Significant premium to history; reflects re-rating from pure distributor to growth platform |
| Fwd P/E (FY2026E) |
~22.6x |
-- |
Reasonable if 15-18% EPS growth sustains; consensus $39.08 vs guide $38.80-$39.20 |
| Fwd P/E (FY2027E) |
~20.1x |
-- |
Attractive for a compounder; Leerink FY2027 EPS est. $44.04 |
| EV/EBITDA (est.) |
~18x |
~14-15x |
Premium; justified by oncology + biopharma services mix shift |
| FCF Yield |
~4.3% |
~5-6% |
Slightly below historical avg; $4.6B midpoint on $108.2B mkt cap |
Catalysts
| # |
Catalyst |
Detail |
| 1 |
GLP-1 Secular Tailwind |
$14B/quarter and growing 26% YoY. Multi-year runway as Novo/Lilly expand indications, supply normalizes, and global adoption increases. MCK invested in 50% refrigeration capacity increase as a competitive moat deepener. |
| 2 |
Oncology Platform Compounding |
37% segment revenue growth, 57% OP growth. FL Cancer Specialists and Prism Vision acquisitions creating a vertically integrated oncology ecosystem with ~3,400 providers in US Oncology Network. |
| 3 |
Med-Surg IPO (H2 CY2027) |
Value unlock catalyst that simplifies the story. TSAs in place as of Jan 1, 2026. Potential for sum-of-the-parts re-rating once the separation is complete. |
| 4 |
AI/Automation Margin Expansion |
Measurable productivity gains: 120 more patients per FTE in verification season, 75% DSCSA inquiry deflection, 138bp improvement in opex/GP ratio. Under-the-radar driver the street has not fully priced. |
| 5 |
Continued Share Buyback |
~$2B/year reducing share count ~3-4% annually. Mechanical EPS accretion from 136.6M shares (CY23Q2) down to 123.7M (CY25Q4). |
| 6 |
FY2027 Guide (May 2026) |
Given the pattern of conservative initial guidance followed by 3 consecutive raises, the FY2027 guide is likely to set up favorably and create a positive sentiment catalyst. |
Key Risks
| # |
Risk |
Severity |
Detail / Mitigant |
| 1 |
Opioid Litigation Tail Risk |
MEDIUM |
$26B settlement largely resolved, but FY2025 still had $108M claims/litigation charge. Rite Aid bankruptcy recovery ($160M credit in Q3) shows ongoing customer credit exposure. Headline risk persists even as financial exposure diminishes. |
| 2 |
Drug Pricing Reform |
MEDIUM |
IRA Part D price changes went live Jan 2026. MFN, Globe, and other proposals create periodic policy overhang. Management says navigable with detailed rebuttal on Q3 call, but political risk is non-zero and creates sentiment drag. |
| 3 |
GLP-1 Concentration Risk |
MEDIUM |
$14B/quarter is substantial exposure to two manufacturers (Novo/Lilly). Supply disruptions, competitive biosimilar entry, or formulary changes could impact growth rate. Mitigant: cold chain investment creates switching costs. |
| 4 |
Valuation Premium |
HIGH |
At ~22-27x earnings, MCK trades well above historical distribution multiples (~18-20x). Any growth disappointment would compress the multiple. The stock needs to continue delivering 15%+ EPS growth to justify the premium. |
| 5 |
Med-Surg Execution |
LOW-MED |
IPO timing dependent on market conditions. Separation costs and TSA complexity could create near-term friction. Segment growing only 1% YoY, raising questions about standalone attractiveness. |
| 6 |
Gross Margin Dilution |
LOW-MED |
GLP-1 and high-revenue/low-margin distribution growth compresses gross margin % even as gross profit dollars grow. GM fell from 4.70% to 3.47% over 8 quarters. Optically concerning to some investors despite being structurally benign. |
Score Rationale
Score of 7.3/10 reflects a strong catalyst pipeline balanced against a meaningful valuation premium and moderate but manageable risk factors. The setup is favorable: GLP-1 distribution is a secular multi-year tailwind, the oncology platform is compounding at 37% revenue growth, and management has raised EPS guidance every quarter for three consecutive fiscal years. The AI/automation efficiency gains are an underappreciated margin expansion driver that the street has not broadly incorporated into models.
The score settles at 7.3 (rather than higher) due to three factors: (1) the valuation premium at ~22-27x earnings is the primary constraint -- MCK trades well above its historical ~18-20x range for a distribution business, and any growth miss could trigger a meaningful de-rate; (2) GLP-1 concentration at $14B/quarter creates meaningful single-product-category exposure to two manufacturers; and (3) opioid litigation, while largely resolved via the $26B settlement, continues to generate headline risk and residual charges. The biggest structural risks are behind the company, the catalyst pipeline is deep, and the under-promise/over-deliver management culture provides confidence in forward estimates -- but the starting valuation demands continued execution with limited room for error.